PRF Technologies (PRFX) Non-Current Assets (2019 - 2025)
PRF Technologies (PRFX) posted quarterly Non-Current Assets of $7.6 million for Q4 2025, up 69418.18% year-on-year from N/an in Q4 2024, and up 5.43% on a QoQ basis from $7.3 million in Q2 2025.
PRF Technologies (PRFX) Non-Current Assets (2019 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Non-Current Assets for 7 consecutive years, with $7.6 million the latest figure, recorded in Q4 2025.
- Quarterly Non-Current Assets rose 69418.18% year-over-year to $7.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.8 million (up 70545.45% YoY) and the FY2025 annual result came in at $7.6 million, up 69418.18% from the prior year.
- Non-Current Assets improved to $7.6 million in Q4 2025 per PRFX's latest filing, from $7.3 million in the prior quarter.
- Over the last five years, Non-Current Assets for PRFX reached as high as $7.6 million in Q4 2025 and fell as low as $11000.0 in Q4 2024.
- A 5-year average of $924352.9 and a median of $44000.0 in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets plunged 91.24% — and 2025, when it soared 69418.18%.
- Year by year, Non-Current Assets stood at $53000.0 in 2021, then dropped by 16.98% to $44000.0 in 2022, then plunged by 59.09% to $18000.0 in 2023, then tumbled by 38.89% to $11000.0 in 2024, then surged by 69418.18% to $7.6 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $7.6 million, $7.3 million, and $11000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | 7.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.65 Mn |
| Jun 30, 2025 | 7.25 Mn |
| Dec 31, 2024 | 11,000.00 |
| Jun 30, 2024 | 115,000.00 |
| Mar 31, 2024 | 124,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Sep 30, 2023 | 146,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Mar 31, 2023 | 42,000.00 |
| Dec 31, 2022 | 44,000.00 |
| Sep 30, 2022 | 44,000.00 |
| Jun 30, 2022 | 54,000.00 |
| Mar 31, 2022 | 51,000.00 |
| Dec 31, 2021 | 53,000.00 |
| Sep 30, 2021 | 28,000.00 |
| Jun 30, 2021 | 24,000.00 |
| Mar 31, 2021 | 22,000.00 |
| Dec 31, 2020 | 10,000.00 |
| Jun 30, 2020 | 274,000.00 |
| Dec 31, 2019 | 192,000.00 |